2026-04-14T11:22:16-05:00 2025-06-30 135565207 KPMG LLP TWO MANHATTAN WEST 375 9TH AVENUE NEW YORK NY 10001 990 2024-07-01 231907729 BREAKTHROUGH T1D BREA 8005332873 200 VESEY STREET 28TH FLOOR NEW YORK NY 10281 MAGGIE MORRIS CHIEF FINANCIAL OFFICER 2124797550 2026-04-08 1 0 EVAN W SEEKAMP P01907071 2127589700 2026-04-03 2024 2025-03-06 01:10:19Z MAGGIE MORRIS 200 VESEY STREET NEW YORK NY 10281 462138789 0 X WWW.BREAKTHROUGHT1D.ORG X 1970 PA IMPROVING LIVES BY ACCELERATING BREAKTHROUGHS TO CURE, PREVENT AND TREAT T1D. SEE SCHEDULE O. 15 15 688 235000 30356 11231 211575057 277038853 21841702 0 23163370 13791709 1535328 10893411 258115457 301723973 97664746 121747047 0 0 78986288 93001616 1254831 1026168 50587659 54224289 65238070 232130154 281012901 25985303 20711072 488117647 534558002 157047946 183982081 331069701 350575921 X BREAKTHROUGH T1D IS THE LEADING GLOBAL T1D ORGANIZATION WORKING TO ACCELERATE LIFE-CHANGING BREAKTHROUGHS TO CURE, PREVENT, AND TREAT T1D AND ITS COMPLICATIONS. 0 0 121747047 121747047 0 RESEARCH FUNDING -- FOR THE YEAR ENDED JUNE 30, 2025, BREAKTHROUGH T1D (FORMERLY JDRF) DIRECTLY FUNDED RESEARCH GRANTS AND INDUSTRY AGREEMENTS FOR WHICH $121.1 MILLION IN RESEARCH GRANT EXPENSE, NET WAS RECOGNIZED ACCORDING TO GAAP IN ADDITION TO $15.5 MILLION OF PROGRAMMATIC RESEARCH INVESTMENTS THAT ARE RECORDED ON BREAKTHROUGH T1D'S BALANCE SHEET. FOR AN EXPANDED DESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO DIRECT RESEARCH FUNDING, SEE SCHEDULE O. 59332584 PUBLIC EDUCATION -- BREAKTHROUGH T1D (FORMERLY JDRF) EDUCATES THE COMMUNITY ABOUT TYPE 1 DIABETES (T1D) AND ITS COMPLICATIONS AND PROVIDES SUPPORT SERVICES AND RESOURCES TO DIAGNOSED CHILDREN AND ADULTS, THEIR FAMILIES, AND OTHERS. FOR AN EXPANDED DESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO PUBLIC EDUCATION AND OUTREACH, SEE SCHEDULE O. 29460942 RESEARCH SUPPORT -- BREAKTHROUGH T1D (FORMERLY JDRF) MAINTAINS AN IN-HOUSE TEAM OF SKILLED SCIENTIFIC, MEDICAL, POLICY, AND GOVERNMENT RELATIONS PROFESSIONALS WHO PLAY A CRITICAL ROLE IN LEADING AND SUPPORTING THE EVALUATION OF RESEARCH FUNDING OPPORTUNITIES BY BREAKTHROUGH T1D AND INFLUENCING RESEARCH DIRECTION AND THE DISBURSEMENT OF RESEARCH FUNDS FROM OTHERS. THESE PROFESSIONALS ALSO WORK WITH REGULATORY AND POLICY OFFICIALS TO ENSURE THAT RESEARCH CAN PROCEED WITHOUT DELAY AND RESULTS ARE UNDERSTOOD BY HEALTHCARE DECISION MAKERS. FOR AN EXPANDED DESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO RESEARCH SUPPORT, SEE SCHEDULE O. 210540573 1 1 0 1 0 0 0 0 0 1 1 0 1 0 1 1 0 1 0 1 1 1 0 1 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 1 622 2 1 688 1 1 1 0 0 0 0 1 1 1 2 0 0 1 0 0 0 X 15 15 0 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 AL AK AZ AR CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC TN TX UT VT VA WA WV WI WY X X MAGGIE MORRIS 8005332873 200 VESEY STREET 28TH FLOOR NEW YORK NY 10281 LISA WALLACK CHAIR 5.00 0.00 X X 0 0 0 MATT VAREY VICE CHAIR 5.00 0.00 X X 0 0 0 MICHAEL ALTER BOARD MEMBER 3.00 0.00 X 0 0 0 ELIZABETH CASWELL CHAIR, TALENT & COMP. COMM. 5.00 0.00 X 0 0 0 CLAUDIA GRAHAM PHD BOARD MEMBER 3.00 0.00 X 0 0 0 MIKE GORDON BOARD MEMBER (START 7/24) 3.00 0.00 X 0 0 0 MICHELLE GRIFFIN BOARD MEMBER 3.00 0.00 X 0 0 0 KAREN JORDAN CHAIR, FINANCE & INVESTMENT COMMITTEE 5.00 0.00 X 0 0 0 JOE LACHER JR BOARD MEMBER 3.00 0.00 X 0 0 0 PER LUNDIN BOARD MEMBER (START 7/24) 3.00 0.00 X 0 0 0 CARLTON MCMILLAN BOARD MEMBER 3.00 0.00 X 0 0 0 JENNIFER SCHNEIDER MD CHAIR, MISSION IMPACT COMM. 5.00 0.00 X 0 0 0 CHRISTOPHER TURNER CHAIR, NOMINATING & GOV. COMM. 5.00 0.00 X 0 0 0 DRAYTON VIRKLER BOARD MEMBER 3.00 0.00 X 0 0 0 KAREY L WITTY BOARD MEMBER 3.00 0.00 X 0 0 0 AARON KOWALSKI CHIEF EXECUTIVE OFFICER 50.00 0.00 X 978057 0 70695 JESSE RABEN CHIEF LEGAL & RISK OFC, SECRETARY 50.00 0.00 X 319780 0 63802 ROBERT KING CFAO/TREASURER (END 1/25) 50.00 0.00 X 562889 0 17682 MARGARET MORRIS CFO, TREASURER (START 3/25) 50.00 0.00 X 248864 0 30896 ANNETTE FREYTAG CHIEF OF STAFF, TREAS (1/25-3/25) 50.00 0.00 X 79666 0 9530 KATHLEEN SEITZ CHIEF GLOBAL DEVELOPMENT OFFICER 50.00 0.00 X 491837 0 68118 SANJOY DUTTA PHD CHIEF SCIENTIFIC OFFICER 50.00 0.00 X 460316 0 20141 STEVEN ST PETER MANAGING DIR. T1D FUND (END 1/25) 50.00 0.00 X 807240 0 52820 AMY MONTALTO VICE PRESIDENT, VOLUNTEER ENGAGEMENT 50.00 0.00 X 296802 0 13516 HARDIK SANGHVI VP, ENTERPRISE ARCHITECTURE AND SE 50.00 0.00 X 296283 0 51906 LYNN STARR CHIEF GLOBAL ADVOCACY OFFICER 50.00 0.00 X 460919 0 44490 PAMELA MORRISROE CHIEF MARKETING OFFICER 50.00 0.00 X 520341 0 44002 TRACY MIDO CHIEF HUMAN RESOURCES OFFICER 50.00 0.00 X 407842 0 15242 JAMES MCDONALD FORMER OFFICER 0.00 0.00 X 148875 0 7651 SYDNEY YOVIC FORMER OFFICER 0.00 0.00 X 296404 0 36025 HELEN ELLIAS FORMER KEY EMPLOYEE 0.00 0.00 X 603815 0 57927 6979930 0 604443 242 1 1 0 BEYOND TECHNOLOGIES LLC 201 N ILLINOIS ST 16TH FLOOR INDIANAPOLIS IN 46204 IT CONSULTING 1195891 CENTRIC CONSULTING LLC PO BOX 75581 CLEVELAND OH 44104 IT CONSULTING 695653 NORTHCAP CONSULTING LLC 8951 CYPRESS WATERS BLVD SUITE 160 COPPELL TX 75019 IT CONSULTING 661064 AVALERE HEALTH LLC 1201 NEW YORK AVE NW SUITE 1000 WASHINGTON DC 20005 BUSINESS CONSULTING 469932 STEPHANIE A RELKIN LLC 96 CARLYLE PLACE ROSLYN HEIGHTS NY 11577 MARKETING CONSULTING 402500 34 3058533 102975270 171005050 6273677 277038853 12755404 30356 12725048 442107 442107 33780 0 33780 33780 33780 140611240 139574935 1036305 1036305 1036305 30209520 102975270 20839881 9369639 9369639 GRANT REFUNDS & ADJUST 813212 598774 598774 MISC REVENUE 900099 449111 449111 1047885 301723973 0 30356 24654764 78831026 78831026 42916021 42916021 4702969 2471823 1479427 751719 70875399 39994549 8816885 22063965 2168257 1198337 268399 701521 10216345 5500168 1399147 3317030 5038646 2784806 684137 1569703 783099 60964 602740 119395 343353 343353 659860 659860 1026168 1026168 704374 704374 17034873 9988582 1422768 5623523 10930666 8242110 516073 2172483 2088794 1271116 231255 586423 5529416 3035707 931316 1562393 4845694 2766182 614273 1465239 6050421 3801055 518788 1730578 4031138 1773438 215148 2042552 15640 9726 1686 4228 3794671 2154378 525541 1114752 647097 345187 107561 194349 FUNDR. POSTAGE & PRINT 3344390 3344390 DUES, FEES, & SUB 2787157 1572415 399956 814786 1647427 1163123 101842 382462 281012901 210540573 19884669 50587659 X 6719073 1679768 0 5039305 2761954 971356 11061849 12788827 59146772 108969528 4222183 5957319 5456587 5811378 11341060 7923134 38535007 31303903 7660248 7231104 308741402 298185164 363245 334106 60188873 65519305 17173474 20866781 488117647 534558002 17099900 19587861 113596253 138372793 4696215 434205 21655578 25587222 157047946 183982081 X 262669904 230683410 68399797 119892511 331069701 350575921 488117647 534558002 20711072 -1204852 0 X 0 1 X 1 0 X 190647071 203302047 189472784 211575057 277038853 1072035812 190647071 203302047 189472784 211575057 277038853 1072035812 6435746 1065600066 2297884 2679458 8011697 13308628 13200935 39498602 58494 72762 23845 30420 11231 196752 3345522 22507054 23469681 16111383 1047885 66481525 1178212691 0.90440 0.91110 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: PROGRAM RELATED INVESTMENT INCOME OTHER EXCLUDED INCOME - 2020 AMOUNT: $ 3,345,522. 2021 AMOUNT: $ 22,507,054. 2022 AMOUNT: $ 23,469,681. 2023 AMOUNT: $ 16,111,383. 2024 AMOUNT: $ 1,047,885. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 0 0 1 2652 0 0 1 633469 0 1 23739 659860 0 PART II-B, LINE 1: GENERAL STATEMENT OF ACTIVITIES BREAKTHROUGH T1D IS THE LEADING GLOBAL ORGANIZATION FUNDING TYPE 1 DIABETES (T1D) RESEARCH, FOCUSED ON CURING T1D AND IMPROVING LIVES. BREAKTHROUGH T1D'S ADVOCACY INCLUDES NON-PARTISAN LOBBYING ACTIVITY TO ENSURE CONGRESS CONTINUES TO INVEST IN CRITICALLY IMPORTANT MEDICAL RESEARCH AND PUTS IN PLACE POLICIES TO ADVANCE DEVELOPMENT AND ACCESS TO THERAPIES TO CURE T1D AND HELP PEOPLE STAY AS HEALTHY AS POSSIBLE UNTIL THAT DAY. BREAKTHROUGH T1D HAS BEEN INSTRUMENTAL IN SECURING THE RENEWAL OF THE SPECIAL DIABETES PROGRAM, WHICH PROVIDES $150M ANNUALLY FOR T1D RESEARCH AT THE NATIONAL INSTITUTES OF HEALTH. BREAKTHROUGH T1D STAFF AND VOLUNTEERS COMMUNICATE WITH GOVERNMENT OFFICIALS THROUGH EMAIL, PHONE CALLS, AND MEETINGS, TO EDUCATE THEM ON ISSUES AND ENCOURAGE THE ADVANCEMENT OF LEGISLATION. FY25 LOBBYING ACTIVITIES DO NOT REPRESENT A SUBSTANTIAL PART OF THE ORGANIZATION'S OVERALL ACTIVITIES. 8359292 998512 549743 8808061 7872557 790019 303284 8359292 7584083 503698 215224 7872557 8911983 25000 -1144983 207917 7584083 7709169 2111094 908280 8911983 0.00000 1.00000 0.00000 0 0 2684066 1100619 1583447 32629464 30203284 2426180 3221477 3221477 7231104 T1D FUND PROGRAM RELATED INVESTMENTS 65519305 F 65519305 LIABILITIES RELATED TO SPLIT-INTEREST AGREEMENTS 2486128 OPERATING & FINANCE LEASE LIABILITY 23101094 25587222 X 299773844 -1204854 557872 -646982 300420826 704374 598774 1303148 301723974 280267624 557872 -598775 -40903 280308527 704374 704374 281012901 PART V, LINE 4: ORGANIZATION'S ENDOWMENT FUNDS THE ORGANIZATION UTILIZES EARNINGS ON ENDOWMENT FUNDS IN THE MANNER SPECIFIED BY THE DONOR AND/OR FOR SUPPORTING THE ORGANIZATION'S GENERAL EXEMPT PURPOSE. PART X, LINE 2: UNCERTAIN TAX POSITIONS BREAKTHROUGH T1D IS A NOT-FOR-PROFIT ORGANIZATION EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE (IRC) AND IS ORGANIZED UNDER THE LAWS OF THE COMMONWEALTH OF PENNSYLVANIA. THE EFFECT OF INCOME TAX POSITIONS IS RECOGNIZED ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT OF BEING SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO BREAKTHROUGH T1D'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER IRC SECTION 511. BREAKTHROUGH T1D'S UNRELATED BUSINESS INCOME TAX LIABILITY WAS INSIGNIFICANT FOR THE YEARS ENDED JUNE 30, 2025 AND 2024. PART XI, LINE 4B - OTHER ADJUSTMENTS: GRANT REFUNDS & ADJUSTMENTS 598,774. 1 EAST ASIA AND THE PACIFIC 0 0 GRANTMAKING RESEARCH GRANTS 5784177 EAST ASIA AND THE PACIFIC 0 1 PROGRAM SERVICES RESEARCH SUPPORT 32109 EAST ASIA AND THE PACIFIC 0 0 INVESTMENTS INVESTMENTS 1473196 EUROPE 0 0 GRANTMAKING RESEARCH GRANTS 24460061 EUROPE 0 4 PROGRAM SERVICES RESEARCH SUPPORT 642183 EUROPE 0 0 FUNDRAISING ACTIVITIES FUNDRAISING ACTIVITIES 168720 EUROPE 0 0 INVESTMENTS INVESTMENTS 11300729 MIDDLE EAST AND NORTH AFRICA 0 0 GRANTMAKING RESEARCH GRANTS 2138867 NORTH AMERICA 0 0 GRANTMAKING RESEARCH GRANTS 8903108 NORTH AMERICA 0 0 INVESTMENTS INVESTMENTS 5200950 SOUTH ASIA 0 0 GRANTMAKING RESEARCH GRANTS 1629808 0 5 0 0 0 5 46000042 15733866 61733908 EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 30000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 42000 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA T1D RESEARCH 160000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 889236 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 300000 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC T1D RESEARCH 505665 CHECK/WIRE TRANSFER 0 N/A N/A SOUTH ASIA T1D RESEARCH 193500 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 1577686 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA T1D RESEARCH 299987 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 89250 CHECK/WIRE TRANSFER 0 N/A N/A MIDDLE EAST AND NORTH AFRICA T1D RESEARCH 324995 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 397351 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC T1D RESEARCH 250000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 471940 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC T1D RESEARCH 800000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 1750000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 154000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 55000 CHECK/WIRE TRANSFER 0 N/A N/A SOUTH ASIA T1D RESEARCH 200000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 230648 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 549828 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 265000 CHECK/WIRE TRANSFER 0 N/A N/A MIDDLE EAST AND NORTH AFRICA T1D RESEARCH 250000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 1176942 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 331484 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 362993 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 302394 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 676538 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 253000 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA T1D RESEARCH 300000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 180000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 307048 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 196306 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 598967 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 219934 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 249909 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 773583 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 783325 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA T1D RESEARCH 57000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 318000 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC T1D RESEARCH 369222 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 45879 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 79765 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 566320 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 665000 CHECK/WIRE TRANSFER 0 N/A N/A MIDDLE EAST AND NORTH AFRICA T1D RESEARCH 313872 CHECK/WIRE TRANSFER 0 N/A N/A MIDDLE EAST AND NORTH AFRICA T1D RESEARCH 1000000 CHECK/WIRE TRANSFER 0 N/A N/A MIDDLE EAST AND NORTH AFRICA T1D RESEARCH 250000 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC T1D RESEARCH 1188307 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 371628 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA T1D RESEARCH 378641 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA T1D RESEARCH 563596 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC T1D RESEARCH 519562 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA T1D RESEARCH 929470 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC T1D RESEARCH 177555 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA T1D RESEARCH 1735027 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 749610 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC T1D RESEARCH 81031 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC T1D RESEARCH 988355 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC T1D RESEARCH 200000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 110000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 199500 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 717078 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 161500 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 455681 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA T1D RESEARCH 3872304 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 979827 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 671882 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 465377 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 419602 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 911224 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 655785 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA T1D RESEARCH 89127 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC T1D RESEARCH 200000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 750000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 171799 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 199841 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 398955 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 78710 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 188862 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA T1D RESEARCH 267955 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 714461 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC T1D RESEARCH 263140 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) T1D RESEARCH 199410 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC T1D RESEARCH 91340 CHECK/WIRE TRANSFER 0 N/A N/A SOUTH ASIA T1D RESEARCH 1236308 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC T1D RESEARCH 150000 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA T1D RESEARCH 250000 CHECK/WIRE TRANSFER 0 N/A N/A 0 88 1 0 1 0 0 1 PART I, LINE 2: GRANT MONITORING PROCEDURES RESEARCH GRANTS ARE AWARDED BY BREAKTHROUGH T1D WITH THE SUPPORT OF BREAKTHROUGH T1D'S RESEARCH COMMITTEE COMPRISED OF BREAKTHROUGH T1D BOARD MEMBERS AND OTHER VOLUNTEERS FOLLOWING THE RECOMMENDATIONS OF AN IN-HOUSE TEAM OF PROFESSIONAL SCIENTIFIC STAFF AND WITH INPUT FROM EXTERNAL SCIENTIFIC REVIEWERS. THE REVIEW PROCESS INCLUDES THE FOLLOWING CRITERIA: (1) THE SCIENTIFIC MERIT OF THE PROPOSED RESEARCH OUTLINED IN A GRANT APPLICATION AND (2) THE RELATIONSHIP OF THE PROPOSED RESEARCH TO BREAKTHROUGH T1D'S GOAL TO IMPROVE LIVES TODAY AND TOMORROW BY ACCELERATING LIFE-CHANGING BREAKTHROUGHS TO CURE, PREVENT AND TREAT T1D AND ITS COMPLICATIONS. THE SCIENTIFIC RESEARCH TEAM AND GRANT ADMINISTRATION STAFF MAINTAIN CLOSE CONTACT WITH GRANTEES, PROVIDING ADVICE AND EVALUATION, REVIEWING PROGRESS REPORTS, REVIEWING RESEARCH EXPENDITURES VERSUS AGREED BUDGETS, AND HELPING DISSEMINATE RESEARCH RESULTS. PART I, LINE 3, COLUMN (F): AMOUNTS IN COLUMN F ARE REPORTED ON AN ACCRUAL BASIS IN LINE WITH THE ORGANIZATION'S AUDITED FINANCIAL STATEMENTS. INVESTMENTS ARE REPORTED AT FAIR MARKET VALUE. PART II, LINES 2 AND 3 WHILE MANY FOREIGN GRANTEES MAY BE RECOGNIZED AS CHARITIES IN THEIR RESPECTIVE COUNTRY OR AS 501(C)(3) ORGANIZATIONS BY THE IRS, BREAKTHROUGH T1D DOES NOT HAVE A FEASIBLE WAY TO VALIDATE FOREIGN TAX EXEMPTION AND CONSERVATIVELY CLASSIFIES ALL FOREIGN GRANTEES AS OTHER. X X X X X X 1 BLUE STATE DIGITAL 41 FLATBUSH AVENUE 8TH FL BROOKLYN NY 11217 DIRECT APPEAL FUNDRAISING SERVICES 0 3421171 574485 2846686 THE PURSUANT GROUP 15660 NORTH DALLAS PARKWAY SUITE 1 DALLAS TX 75248 DIRECT APPEAL FUNDRAISING SERVICES 0 2745610 352380 2393230 CASWELL ZACHRY GRIZZARD 6301 GASTON AVENUE SUITE 715 DALLAS TX 75214 PLANNED GIVING MARKETING 0 0 107423 -107423 SYNERGY DIRECT MARKETING SOLUTIONS LLC 480 WEST TUSCARAWAS AVE SUITE 307 BARBERTON OH 44203 TEXT MESSAGING CAMPAIGN 0 0 2168 -2168 6166781 1036456 5130325 AL AK AZ AR CA CO CT DC FL GA HI IL KS KY LA ME MD MA MI MN MS MO NV NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI ILLINOIS GALA 17307941 15818332 1489609 8500 156936 433008 672379 2003 BEAT THE BRIDGE WALK 2848320 2848320 1338 47734 1075 36377 36074 304 113028529 84308618 28719911 44163 1482230 6214128 4482162 6302460 919314 133184790 102975270 30209520 44163 1492068 6418798 4916245 7011216 957391 20839881 9369639 PART I, LINE 2: BREAKTHROUGH T1D PAID FUNDRAISING EXPENSES OF $932,721 FOR POSTAGE AND $2,314,414 FOR PRINTING TO THE PURSUANT GROUP. THE INVOICES PROVIDE AN ITEMIZED LIST OF SERVICES AND EXPENSES. PART I, LINE 2: BREAKTHROUGH T1D PAID FUNDRAISING EXPENSES OF $15,488 FOR POSTAGE AND $81,647 FOR PRINTING TO CASWELL. THE INVOICES PROVIDE AN ITEMIZED LIST OF SERVICES AND EXPENSES. 1 ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVENUE BELFER 312 BRONX NY 10461 830621846 501(C)(3) 373268 0 N/A N/A T1D RESEARCH ANN & ROBERT H LURIE CHILDRENS HOSPITAL OF CHICAGO 225 EAST CHICAGO AVENUE CHICAGO IL 60611 362170833 501(C)(3) 489549 0 N/A N/A T1D RESEARCH ARIZONA BOARD OF REGENTS UNIVERSITY OF ARIZONA PO BOX 3520 TUCSON AZ 857223520 742652689 501(C)(3) 1320967 0 N/A N/A T1D RESEARCH BAYLOR COLLEGE OF MEDICINE PO BOX 301207 DALLAS TX 78759 741613878 501(C)(3) 690369 0 N/A N/A T1D RESEARCH BAYLOR RESEARCH INSTITUTE PO BOX 301207 DALLAS TX 78759 751921898 501(C)(3) 249939 0 N/A N/A T1D RESEARCH BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE 1500 E DUARTE RD DUARTE CA 91010 953432210 501(C)(3) 1276538 0 N/A N/A T1D RESEARCH BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON 1201 NINTH AVENUE SEATTLE WA 98101 910653422 501(C)(3) 452396 0 N/A N/A T1D RESEARCH BETH ISRAEL DEACONESS MEDICAL CENTER INC PO BOX 15707 330 BROOKLINE AVENUE BOSTON MA 02215 042103881 501(C)(3) 300000 0 N/A N/A T1D RESEARCH BIOLOGICS CONSULTING GROUP INC 1555 KING STREET SUITE 300 ALEXANDRIA VA 22314 841693476 N/A 124950 0 N/A N/A T1D RESEARCH BOSTON CHILDREN'S HOSPITAL PO BOX 414413 BOSTON MA 02241 042774441 501(C)(3) 933731 0 N/A N/A T1D RESEARCH CALIFORNIA INSTITUTE OF TECHNOLOGY 1200 E CALIFORNIA BLVD MAIL CODE 2 PASADENA CA 911250001 951643307 501(C)(3) 250000 0 N/A N/A T1D RESEARCH CARNEGIE MELLON UNIVERSITY 5000 FORBES AVENUE PITTSBURGH PA 15213 250969449 501(C)(3) 625000 0 N/A N/A T1D RESEARCH CASE WESTERN RESERVE UNIVERSITY 10900 EUCLID AVENUE STE 357 CLEVELAND OH 441067001 341018992 501(C)(3) 200000 0 N/A N/A T1D RESEARCH CLINTON HEALTH ACCESS INITIATIVE (CHAI) 383 DORCHESTER AVE STE 300 BOSTON MA 02127 271414646 501(C)(3) 1734554 0 N/A N/A T1D RESEARCH COLORADO SCHOOL OF MINES 1500 ILLINOIS ST GOLDEN CO 80401 846000551 501(C)(3) 300000 0 N/A N/A T1D RESEARCH COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK PO BOX 29789-GENERAL POST OFFICE NEW YORK NY 100879789 135598093 501(C)(3) 382730 0 N/A N/A T1D RESEARCH CONVERGENCE LLC 1015 15TH STREET NW ST 600 WASHINGTON DC 20006 320280279 N/A 60000 0 N/A N/A T1D RESEARCH DARK HORSE CONSULTING 1255 TREAT BLVD SUITE 230 WALNUT CREEK CA 94597 320574597 N/A 162395 0 N/A N/A T1D RESEARCH DIATECH DIABETES INC 88 UNION AVE MEMPHIS TN 38103 841890342 N/A 75000 0 N/A N/A T1D RESEARCH DUKE UNIVERSITY 2138 CAMPUS DRIVE BOX 90586 DURHAM NC 27708 560532129 501(C)(3) 616138 0 N/A N/A T1D RESEARCH EAST TENNESSEE STATE UNIVERSITY 1276 GILBREATH DR BOX 70300 JOHNSON CITY TN 37614 626021046 501(C)(3) 147312 0 N/A N/A T1D RESEARCH EMORY UNIVERSITY PO BOX 935084- ATLANTA GA 311935084 580566256 501(C)(3) 300000 0 N/A N/A T1D RESEARCH EVOQ THERAPEUTICS INC 1600 HURON PARKWAY BLDG 520 2ND FL ANN ARBOR MI 48109 813291966 N/A 300000 0 N/A N/A T1D RESEARCH GEORGIA TECH RESEARCH CORPORATION 505 10TH ST NW ATLANTA GA 303185775 580603146 501(C)(3) 329008 0 N/A N/A T1D RESEARCH GINER INC 89 RUMFORD AVE NEWTON MA 02466 821416958 N/A 25000 0 N/A N/A T1D RESEARCH HUGO W MOSER RESEARCH INSTITUTE AT KENNEDY KRIEGER 1741 ASHLAND AVENUE 7TH FLOOR BALTIMORE MD 21205 521524967 501(C)(3) 65000 0 N/A N/A T1D RESEARCH ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI PO BOX 371220 PITTSBURGH PA 15251 136171197 501(C)(3) 1868623 0 N/A N/A T1D RESEARCH INDIANA BIOSCIENCES RESEARCH INSTITUTE 1210 WATERWAY BLVD STE 2000 INDIANAPOLIS IN 46202 462882271 501(C)(3) 448353 0 N/A N/A T1D RESEARCH INTEGRATED MEDICAL SENSORS INC 30 HUGHES SUITE 200 IRVINE CA 92618 474751319 N/A 50000 0 N/A N/A T1D RESEARCH IQVIA INC 100 IMS DRIVE PARSIPPANY NJ 07054 271341991 N/A 345083 0 N/A N/A T1D RESEARCH ITOLERANCE INC 1951 NW 7TH AVE STE 300 MIAMI FL 33136 853086959 N/A 35000 0 N/A N/A T1D RESEARCH JAEB CENTER FOR HEALTH RESEARCH 15310 AMBERLY DR STE 350 SUITE 350 TAMPA FL 33647 593187624 501(C)(3) 150000 0 N/A N/A T1D RESEARCH JOHNS HOPKINS UNIVERSITY 3400 N CHARLES STREET BALTIMORE MD 21218 520595110 501(C)(3) 827230 0 N/A N/A T1D RESEARCH JOSLIN DIABETES CENTER INC ONE JOSLIN PLACE BOSTON MA 022155306 042203836 501(C)(3) 2565662 0 N/A N/A T1D RESEARCH KINEXUM LLC BOX 1260 550 RIDGE STREET HARPERS FERRY WV 25425 743079796 N/A 160000 0 N/A N/A T1D RESEARCH LABCENTRAL 700 MAIN STREET N CAMBRIDGE MA 02139 461031913 501(C)(3) 200000 0 N/A N/A T1D RESEARCH MAGNOLIA INNOVATION LLC 200 CROSSING BLVD BRIDGEWATER NJ 08807 463494625 N/A 434000 0 N/A N/A T1D RESEARCH MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT ST BLDG 149 13TH STREET CNY-3601 BOSTON MA 02114 042697983 501(C)(3) 421875 0 N/A N/A T1D RESEARCH MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVENUE NE 49-3131 CAMBRIDGE MA 021394307 042103594 501(C)(3) 169244 0 N/A N/A T1D RESEARCH MAYO CLINIC PO BOX 860334 MINNEAPOLIS MN 55486 416011702 501(C)(3) 349373 0 N/A N/A T1D RESEARCH MEMORIAL SLOAN-KETTERING CANCER CENTER MSK DEVELOPMENT OFFICE P O BOX 27106 NEW YORK NY 10065 131924236 501(C)(3) 250000 0 N/A N/A T1D RESEARCH MICHIGAN STATE UNIVERSITY 426 AUDITORIUM RD HANNAH ADMIN BLDG ROOM 50 EAST LANSING MI 488242604 386005984 501(C)(3) 250000 0 N/A N/A T1D RESEARCH MILLIMAN 1301 5TH AVE STE 3800 SEATTLE WA 98101 910675641 N/A 870000 0 N/A N/A T1D RESEARCH MINUTIA 535 BELLEVUE AVE OAKLAND CA 946105033 851020286 N/A 140000 0 N/A N/A T1D RESEARCH MISSOURI UNIVERSITY OF SCIENCE AND TECHNOLOGY 1201 N STATE ST CURATORS OFFICE ROLLA MO 65409 436003859 501(C)(3) 236055 0 N/A N/A T1D RESEARCH MOSAIC BIOSCIENCES INC 5710 FLATIRON PKWY BOULDER CO 80301 271127073 N/A 293674 0 N/A N/A T1D RESEARCH NEMOURS CHILDREN'S CLINIC 10140 CENTURION PARKWAY NORTH JACKSONVILLE FL 32256 590634433 501(C)(3) 212296 0 N/A N/A T1D RESEARCH NEURODON LLC 9800 CONNECTICUT DRIVE CROWN POINT IN 46307 465375254 N/A 83000 0 N/A N/A T1D RESEARCH NEW YORK STEM CELL FOUNDATION INC 619 WEST 54TH STREET 3RD FLOOR NEW YORK NY 10019 202905531 501(C)(3) 478510 0 N/A N/A T1D RESEARCH NORTHWESTERN UNIVERSITY 633 CLARK STREET G-547 EVANSTON IL 602081112 362167817 501(C)(3) 706795 0 N/A N/A T1D RESEARCH OREGON STATE UNIVERSITY 104 KERR ADMINISTRATION BLDG CORVALLIS OR 97331 481278540 501(C)(3) 249829 0 N/A N/A T1D RESEARCH PENN STATE COLLEGE OF MEDICINE 500 UNIVERSITY DRIVE PO BOX 850 HERSHEY PA 17033 246000376 501(C)(3) 242923 0 N/A N/A T1D RESEARCH QUAESTIO GLOBAL PARTNERS LLC ONE KNOLLWOOD TERRACE CHESTER NJ 07930 208396264 N/A 55000 0 N/A N/A T1D RESEARCH RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA PO BOX 400195 CHARLOTTESVILLE VA 22903 546001796 501(C)(3) 1549988 0 N/A N/A T1D RESEARCH REGENTS OF THE UNIVERSITY OF COLORADO 1800 GRANT STREET 8TH FLOOR DENVER CO 80203 846000555 501(C)(3) 3578005 0 N/A N/A T1D RESEARCH REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 S STATE STREET 1002 WOLVERINE TOWER ANN ARBOR MI 48109 386006309 501(C)(3) 2251674 0 N/A N/A T1D RESEARCH REGENTS OF THE UNIVERSITY OF MINNESOTA NW 5957 PO BOX 1450 MINNEAPOLIS MN 554855957 416007513 501(C)(3) 1594731 0 N/A N/A T1D RESEARCH REMD BIOTHERAPEUTICS 4010 ADOLFO ROAD SUITE A CAMARILLO CA 930126793 454614986 N/A 390000 0 N/A N/A T1D RESEARCH RTI INTERNATIONAL PO BOX 14668 RESEARCH TRIANGLE PARK NC 27709 560686338 501(C)(3) 1282552 0 N/A N/A T1D RESEARCH RUTGERS BIOMEDICAL AND HEALTH SCIENCES 65 BERGEN STREET MEDICAL SCIENCE BUILDING ROOM C-690 PISCATAWAY NJ 071073001 226001086 501(C)(3) 318346 0 N/A N/A T1D RESEARCH SEATTLE CHILDRENS HOSPITAL 4800 SAND POINT WAY NE DIVISION OF NEPHROLOGY CH-46 SEATTLE WA 55455 910564748 501(C)(3) 434592 0 N/A N/A T1D RESEARCH STANFORD UNIVERSITY PO BOX 44253 SAN FRANCISCO CA 441444253 941156365 501(C)(3) 1323091 0 N/A N/A T1D RESEARCH T1D EXCHANGE INC 11 AVENUE DE LAFAYETTE 5TH FLOOR BOSTON MA 02111 451623549 501(C)(3) 668884 0 N/A N/A T1D RESEARCH THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA 1720 2ND AVE S BIRMINGHAM AL 35294 636005396 501(C)(3) 249933 0 N/A N/A T1D RESEARCH THE BRIGHAM AND WOMENS HOSPITAL INC 75 FRANCIS STREET BOSTON MA 021156110 042312909 501(C)(3) 2749635 0 N/A N/A T1D RESEARCH THE LUNDQUIST INSTITUTE 1124 WEST CARSON ST TORRANCE CA 90502 952138184 501(C)(3) 149999 0 N/A N/A T1D RESEARCH THE MEDICAL COLLEGE OF WISCONSIN INC 8701 W WATERTOWN PLANK ROAD MILWAUKEE WI 532263548 390806261 501(C)(3) 338260 0 N/A N/A T1D RESEARCH THE METHODIST HOSPITAL RESEARCH INSTITUTE 6670 BERTNER AVE HOUSTON TX 77030 870721923 501(C)(3) 462996 0 N/A N/A T1D RESEARCH THE REGENTS OF THE UNIVERSITY OF CALIFORNIA LOS ANGELES 11000 KINROSS AVE 211 PO BOX 951406 LOS ANGELES CA 900951406 956006143 501(C)(3) 708005 0 N/A N/A T1D RESEARCH THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 1855 FOLSOM ST STE 425 BOX 0897 SAN FRANCISCO CA 94143 946036493 501(C)(3) 5397345 0 N/A N/A T1D RESEARCH THE RESEARCH FOUNDATION OF SUNY ON BEHALF OF UNIVERSITY AT BUFFALO UB COMMONS SUITE 211 520 LEE ENTRANCE AMHERST NY 14228 141368361 501(C)(3) 167208 0 N/A N/A T1D RESEARCH THE SONIA NABETA FOUNDATION PO BOX 2222 NEW YORK NY 100082222 352543949 501(C)(3) 82716 0 N/A N/A T1D RESEARCH THE UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVENUE CHICAGO IL 60637 362177139 501(C)(3) 4120701 0 N/A N/A T1D RESEARCH THE UNIVERSITY OF IOWA GRANT ACCOUNTING OFFICE 2410 UCC 201 S CLINTON ST IOWA CITY IA 522424034 426004813 501(C)(3) 250000 0 N/A N/A T1D RESEARCH THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON 7000 FANNIN ST SUITE 1000 HOUSTON TX 77030 741761309 501(C)(3) 100000 0 N/A N/A T1D RESEARCH TIDEPOOL 555 BRYANT ST 429 PALO ALTO CA 94301 462302287 501(C)(3) 100000 0 N/A N/A T1D RESEARCH TORRAMICS INC 440 N BARRANCA AVE 2897 COVINA CA 91723 872652308 N/A 200000 0 N/A N/A T1D RESEARCH TRUSTEES OF INDIANA UNIVERSITY OFFICE OF RESEARCH ADMINISTRATION 509 E 3RD ST BLOOMINGTON IN 47401 356001673 501(C)(3) 2492689 0 N/A N/A T1D RESEARCH TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 1 COLLEGE HALL ROOM 211 PHILADELPHIA PA 19104 231352685 501(C)(3) 1321090 0 N/A N/A T1D RESEARCH UNIVERSITY OF CALIFORNIA SAN DIEGO UCSD CASHIERS OFFICE-9500 GILMAN DRIVE DEPT 0009 LA JOLLA CA 920930009 956006144 501(C)(3) 402212 0 N/A N/A T1D RESEARCH UNIVERSITY OF CINCINNATI PO BOX 932641 CLEVELAND OH 441930014 316000989 501(C)(3) 502481 0 N/A N/A T1D RESEARCH UNIVERSITY OF FLORIDA 207 GRINTER HALL PO BOX 115500 GAINESVILLE FL 32611 596002052 501(C)(3) 3130295 0 N/A N/A T1D RESEARCH UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC 3901 RAINBOW BLVD KANSAS CITY KS 66160 481108830 501(C)(3) 749999 0 N/A N/A T1D RESEARCH UNIVERSITY OF MARYLAND 4101 CHESAPEAKE BUILDING 4300 TER COLLEGE PARK MD 207423141 526002033 501(C)(3) 329999 0 N/A N/A T1D RESEARCH UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 55 LAKE AVENUE NORTH WORCESTER MA 016550002 043167352 501(C)(3) 7275001 0 N/A N/A T1D RESEARCH UNIVERSITY OF MIAMI 1320 S DIXIE HWY STE 760 212 PEARSON HALL CORAL GABLES FL 331462919 590624458 501(C)(3) 2173204 0 N/A N/A T1D RESEARCH UNIVERSITY OF PITTSBURGH 4200 FIFTH AVE CENTRAL PLANT NO 3 PITTSBURGH PA 15260 250965591 501(C)(3) 449999 0 N/A N/A T1D RESEARCH UNIVERSITY OF UTAH 201 S PRESIDENTS CIRCLE RM 406 PARK BUILDIN SALT LAKE CITY UT 841129023 876000525 501(C)(3) 79765 0 N/A N/A T1D RESEARCH UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVE NE BOX 359472 SEATTLE WA 98105 916001537 501(C)(3) 2386866 0 N/A N/A T1D RESEARCH UNIVERSITY OF WISCONSIN-MADISON UW-MADISON GAR ACCOUNT OFFICE DRAWER538 MILWAUKEE WI 532780538 396006492 501(C)(3) 1307359 0 N/A N/A T1D RESEARCH UT SOUTHWESTERN PO BOX 841753 DALLAS TX 752841753 752556007 501(C)(3) 427191 0 N/A N/A T1D RESEARCH VANDERBILT UNIVERSITY PMB 407749 2301 VANDERBILT PLACE NASHVILLE TN 372407749 620476822 501(C)(3) 274970 0 N/A N/A T1D RESEARCH VANDERBILT UNIVERSITY MEDICAL CENTER (VUMC) 1211 MEDICAL CENTER DR NASHVILLE TN 37203 352528741 501(C)(3) 550473 0 N/A N/A T1D RESEARCH VECTOR PSYCHOMETRIC GROUP PO BOX 29650 PHOENIX AZ 85038 208629825 N/A 481423 0 N/A N/A T1D RESEARCH WAKE FOREST UNIVERSITY HEALTH SCIENCES PO BOX 604096 CHARLOTTE NC 28202 223849199 501(C)(3) 248692 0 N/A N/A T1D RESEARCH WASHINGTON UNIVERSITY BOX 1034-700 ROSEDALE AVE ST LOUIS MO 631121408 430653611 501(C)(3) 675000 0 N/A N/A T1D RESEARCH WAYNE STATE UNIVERSITY 5057 WOODWARD AVE 13TH FL DETROIT MI 482024050 386028429 501(C)(3) 299995 0 N/A N/A T1D RESEARCH WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVE BOX 89 NEW YORK NY 10065 131623978 501(C)(3) 550000 0 N/A N/A T1D RESEARCH WILLIAM MARSH RICE UNIVERSITY 6100 MAIN STREET MS 16 HOUSTON TX 77005 741109620 501(C)(3) 300000 0 N/A N/A T1D RESEARCH YALE UNIVERSITY PO BOX 209010 - 10 AMISTAD ST NEW HAVEN CT 065209010 060646973 501(C)(3) 565925 0 N/A N/A T1D RESEARCH 81 19 PART I, LINE 2: RESEARCH GRANTS ARE AWARDED BY BREAKTHROUGH T1D WITH THE SUPPORT OF BREAKTHROUGH T1D'S RESEARCH COMMITTEE COMPRISED OF BREAKTHROUGH T1D BOARD MEMBERS AND OTHER VOLUNTEERS OR THE BREAKTHROUGH T1D BOARD OF DIRECTORS FOLLOWING THE RECOMMENDATIONS OF AN IN-HOUSE TEAM OF PROFESSIONAL SCIENTIFIC STAFF AND WITH INPUT FROM EXTERNAL SCIENTIFIC REVIEWERS. THE REVIEW PROCESS INCLUDES THE FOLLOWING CRITERIA: (1) THE SCIENTIFIC MERIT OF THE PROPOSED RESEARCH OUTLINED IN A GRANT APPLICATION AND (2) THE RELATIONSHIP OF THE PROPOSED RESEARCH TO BREAKTHROUGH T1D'S GOAL TO IMPROVE LIVES TODAY AND TOMORROW BY ACCELERATING LIFE-CHANGING BREAKTHROUGHS TO CURE, PREVENT AND TREAT T1D AND ITS COMPLICATIONS. THE SCIENTIFIC RESEARCH TEAM AND GRANT ADMINISTRATION STAFF MAINTAIN CLOSE CONTACT WITH GRANTEES, PROVIDING ADVICE AND EVALUATION, REVIEWING PROGRESS REPORTS, REVIEWING RESEARCH EXPENDITURES VERSUS AGREED BUDGETS, AND HELPING DISSEMINATE RESEARCH RESULTS. X 1 0 X X X X X 1 0 0 0 0 0 0 1 0 AARON KOWALSKI CHIEF EXECUTIVE OFFICER 646557 0 294000 0 37500 0 17500 0 53195 0 1048752 0 0 0 STEVEN ST PETER MANAGING DIR. T1D FUND (END 1/25) 417240 0 390000 0 0 0 15938 0 36882 0 860060 0 0 0 HELEN ELLIAS FORMER KEY EMPLOYEE 308815 0 225000 0 70000 0 13125 0 44802 0 661742 0 0 0 ROBERT KING CFAO/TREASURER (END 1/25) 449689 0 113200 0 0 0 16100 0 1582 0 580571 0 0 0 PAMELA MORRISROE CHIEF MARKETING OFFICER 396141 0 124200 0 0 0 14905 0 29097 0 564343 0 0 0 KATHLEEN SEITZ CHIEF GLOBAL DEVELOPMENT OFFICER 387337 0 104500 0 0 0 15068 0 53050 0 559955 0 0 0 LYNN STARR CHIEF GLOBAL ADVOCACY OFFICER 384919 0 76000 0 0 0 15396 0 29094 0 505409 0 0 0 SANJOY DUTTA PHD CHIEF SCIENTIFIC OFFICER 364216 0 96100 0 0 0 10384 0 9757 0 480457 0 0 0 TRACY MIDO CHIEF HUMAN RESOURCES OFFICER 320542 0 87300 0 0 0 12636 0 2606 0 423084 0 0 0 JESSE RABEN CHIEF LEGAL & RISK OFC, SECRETARY 264780 0 55000 0 0 0 6151 0 57651 0 383582 0 0 0 HARDIK SANGHVI VP, ENTERPRISE ARCHITECTURE AND SE 241283 0 55000 0 0 0 5815 0 46091 0 348189 0 0 0 SYDNEY YOVIC FORMER OFFICER 238004 0 58400 0 0 0 6869 0 29156 0 332429 0 0 0 AMY MONTALTO VICE PRESIDENT, VOLUNTEER ENGAGEMENT 270102 0 26700 0 0 0 11934 0 1582 0 310318 0 0 0 MARGARET MORRIS CFO, TREASURER (START 3/25) 214164 0 34700 0 0 0 9941 0 20955 0 279760 0 0 0 JAMES MCDONALD FORMER OFFICER 128675 0 20200 0 0 0 4557 0 3094 0 156526 0 0 0 PART I, LINE 1A HOUSING ALLOWANCE CEO AARON KOWALSKI RECEIVED A TAXABLE HOUSING ALLOWANCE AS PER THE TERMS OF HIS EMPLOYMENT AGREEMENT. THE TOTAL FOR CALENDAR YEAR 2024 WAS $37,500. PART I, LINE 4A SEVERANCE PAYMENTS HELEN ELLIAS RECEIVED SEVERANCE PAYMENT AS PER THE TERMS OF HER EMPLOYMENT AGREEMENT. THE TOTAL IS AS FOLLOWS: HELEN ELLIAS - $70,000 SEVERANCE PAYMENTS ARE REPORTED ON SCHEDULE J, PART II, COLUMN (B)(III) AS OTHER REPORTABLE COMPENSATION. PART I, LINE 7 NON-FIXED PAYMENTS BREAKTHROUGH T1D AWARDS NON-FIXED PAYMENTS SUCH AS BONUSES ON A DISCRETIONARY BASIS TIED TO THE EMPLOYEES' PERFORMANCE. THE NAMES OF EMPLOYEES AND THE AMOUNTS THAT WERE PAID ARE FOUND ON SCHEDULE J, PAGE 2, PART II, COLUMN (B) (II). X 62 70088 NET PROCEEDS OF SALE X 364 6171089 NET PROCEEDS OF SALE X 3 32500 APPRAISED VALUE 2 0 1 1 SCHEDULE M, PART I, LINE 32B THIRD PARTY ASSISTANCE CHARITABLE ADULT RIDES AND SERVICES (CARS) IS A THIRD PARTY CAR DONATION COMPANY THAT HANDLES ALL ASPECTS OF CARS BEING DONATED TO BREAKTHROUGH T1D. DONORS CALL A TOLL FREE NUMBER AND ARE PUT IN CONTACT WITH A TOWING SERVICE IN THEIR AREA. AFTER THE CAR IS DONATED, CARS HANDLES ALL IRS 1098-C REPORTING. FOR THE YEAR ENDED 6/30/2025, CARS RAISED $98,356, WITH SELLING EXPENSES OF $10,746 AND FUNDRAISING SERVICE FEES OF $17,522. BREAKTHROUGH T1D DOES NOT PAY CARS ANY EXPENSES OR FEES DIRECTLY. BREAKTHROUGH T1D RECEIVED $70,088 OF NET REVENUE FROM CARS IN FY 2025. SCHEDULE M, PART I PART I, LINE 9 REPORTS THE NUMBER OF CONTRIBUTIONS OF SECURITIES THAT WERE MADE TO BREAKTHROUGH T1D. FORM 990, PART I, LINE 1 AND PART III, LINE 1 - ORGANIZATION'S MISSION BREAKTHROUGH T1D (FORMERLY JDRF) WORKS TIRELESSLY TO ACCELERATE BREAKTHROUGHS TO CURE, PREVENT, AND BETTER TREAT TYPE 1 DIABETES (T1D) AND ITS COMPLICATIONS. WE CONTINUALLY EXPAND OUR SCIENTIFIC KNOWLEDGE, OUR CONNECTIONS AND COLLABORATIONS, OUR PARTNERS AND GLOBAL PRESENCE TO UNLOCK THE SCIENCE THAT WILL MAKE T1D A THING OF THE PAST. WHILE WE DRIVE TOWARD CURES, WE STRIVE JUST AS HARD TO DEVELOP THERAPIES TO HELP PEOPLE RIGHT NOW. BREAKTHROUGH T1D AND OUR SCIENTISTS ARE LEADING T1D RESEARCH AROUND THE WORLD. WE ADDRESS KEY GAPS TO MOVE RESEARCH FASTER AND FARTHER ACROSS THE DEVELOPMENT AND ACCESS PIPELINE AND TO TRANSLATE BREAKTHROUGHS INTO NEW THERAPIES FOR PEOPLE WITH T1D. THIS ENABLES US TO ADVANCE SCIENCE WITH THE MOST POTENTIAL AND TO DRIVE RESEARCH THAT ATTRACTS MORE RESOURCES AND SCIENTIFIC EXPERTISE TO THE FIELD. WE INVEST IN THE EARLY STAGES, ALLOWING RESEARCHERS TO PURSUE INNOVATIVE IDEAS AND APPROACHES THAT WILL LEAD TO BREAKTHROUGH TREATMENTS. BREAKTHROUGH T1D ALSO WORKS TO DRIVE NEW THERAPIES AND TECHNOLOGIES TO MARKET SO THEY GET INTO THE HANDS OF PEOPLE WITH T1D MORE QUICKLY. WE PARTNER WITH HEALTHCARE PROFESSIONALS TO ESTABLISH AND SOCIALIZE T1D CLINICAL CARE GUIDELINES TAILORED TO REGIONAL NEEDS. WE EDUCATE HEALTHCARE PROFESSIONALS AND PEOPLE WITH T1D ABOUT THERAPIES AND DEVICES SO THEY UNDERSTAND THEIR OPTIONS FOR MANAGING T1D. AND WE CONNECT THE T1D COMMUNITY TO CREATE A GLOBAL COMMUNITY OF SUPPORT FOR ANYONE AFFECTED BY T1D. FROM FUNDING INNOVATIVE RESEARCH TO ADVOCATING FOR GOVERNMENT ACTION AND PROVIDING A SUPPORT STRUCTURE FOR OUR COMMUNITY, NO OTHER ORGANIZATION DOES MORE TO DRIVE TOWARD CURES FOR T1D WHILE MAKING LIFE WITH THE DISEASE BETTER FOR THE PEOPLE WHO FACE IT. SINCE OUR FOUNDING, BREAKTHROUGH T1D HAS FUNDED MORE THAN $2.5 BILLION IN RESEARCH AND HAS MADE SIGNIFICANT PROGRESS IN UNDERSTANDING THE DISEASE, DRIVING TOWARD CURES FOR IT, AND IMPROVING THE LIVES OF PEOPLE WITH IT. OUR ACTIONS - THROUGH ADVOCACY, MEDICAL AFFAIRS, AND OUR OWN INVESTMENTS IN T1D RESEARCH - INFLUENCE OTHER ORGANIZATIONS, CORPORATIONS, AND GOVERNMENT AGENCIES TO FOLLOW OUR LEAD AND DIRECT ADDITIONAL FUNDING TOWARD T1D RESEARCH. TODAY, EVERY $1 BREAKTHROUGH T1D INVESTS IN RESEARCH ATTRACTS AN ADDITIONAL $3.37 TO THE FIELD. FOR FISCAL YEAR 2025, BREAKTHROUGH T1D'S APPROXIMATELY $166 MILLION IN RESEARCH FUNDING AND INVESTMENTS ATTRACTED $562 MILLION IN ADDITIONAL INVESTMENT IN T1D RESEARCH FROM U.S. AND INTERNATIONAL GOVERNMENTS, NONGOVERNMENTAL ORGANIZATIONS AND PEER CHARITABLE ORGANIZATIONS, AND INDUSTRY AND CORPORATE PARTNERS. FORM 990, PART III, LINE 4A: RESEARCH FUNDING BREAKTHROUGH T1D HAS PLAYED A SIGNIFICANT ROLE IN NEARLY EVERY T1D ADVANCEMENT--DRUG, DEVICE, CELL THERAPY--MADE IN THE LAST 50+ YEARS. OUR FUNDING SUPPORTS MORE THAN 450 ACTIVE T1D RESEARCH GRANTS IN THE UNITED STATES AND 20+ OTHER COUNTRIES AROUND THE WORLD, INCLUDING 151 GRANTS IN FY2025 ALONE, PLUS 78 INTERVENTIONAL CLINICAL TRIALS. WE LEVERAGE PARTNERSHIPS WITH ACADEMIA, INDUSTRY, AND CLINICIANS TO ACCELERATE THE MOST PROMISING RESEARCH OPPORTUNITIES. OUR HIGHEST PRIORITY IS DEVELOPING CURES FOR T1D AND IMPROVING LIVES OF THOSE LIVING WITH THE DISEASE TODAY, INCLUDING RESEARCH IN GLUCOSE CONTROL AND PREVENTION AND BETTER TREATMENT OF T1D COMPLICATIONS. THE FULL IMPACT OF BREAKTHROUGH T1D'S RESEARCH INVESTMENT EXTENDS WELL BEYOND DIRECT FUNDING. THROUGH ADVOCACY AND INFLUENCE, BREAKTHROUGH T1D DRIVES FUNDING FROM OTHER SOURCES INTO T1D RESEARCH AND HAS HELPED SECURE PASSAGE OF THE SPECIAL DIABETES PROGRAM, PUTTING NEARLY $3.5 BILLION IN FEDERAL FUNDING TOWARD T1D RESEARCH OVER THE LAST TWO DECADES. ADDITIONALLY IN 2016, BREAKTHROUGH T1D FOUNDED THE T1D FUND: A BREAKTHROUGH T1D VENTURE (T1DFUND.ORG). THE T1D FUND, WHICH IS AN INDEPENDENTLY RUN SUBSIDIARY OF BREAKTHROUGH T1D, IS AN IMPACT INVESTMENT FUND FOCUSED ON ACCELERATING LIFE-CHANGING SOLUTIONS TO TREAT, PREVENT, AND ULTIMATELY CURE TYPE 1 DIABETES (T1D) THROUGH EQUITY INVESTMENTS. FUNDED THROUGH DONATIONS FROM BREAKTHROUGH T1D, OTHER FOUNDATIONS, AND PRIVATE INDIVIDUALS, THE T1D FUND IS A UNIQUE CONSTRUCT THAT INVESTS IN FOR-PROFIT ENTITIES AND REINVESTS RETURNS BACK INTO ADDITIONAL PROMISING OPPORTUNITIES. IN ACCORDANCE WITH GAAP, THE T1D FUND'S TOTAL INVESTMENTS AS OF JUNE 30, 2025, TOTALING $71.3 MILLION, ARE REFLECTED IN THE BALANCE SHEET (PART X) AND NOT INCLUDED WITHIN BREAKTHROUGH T1D'S RESEARCH-RELATED MISSION EXPENSE. BREAKTHROUGH T1D'S DIVERSIFIED RESEARCH PORTFOLIO INCLUDES A FOCUS ON CURING T1D AND IMPROVING LIVES THROUGH THEIR ACADEMIC GRANT FUNDING AND INDUSTRY DISCOVERY & DEVELOPMENT PARTNERSHIP (IDDP) PRODUCT-BASED INITIATIVES FOCUSED ON ALL STAGES OF RESEARCH. CURING T1D WE FACE TWO KEY CHALLENGES IN CURING T1D. WE MUST PREVENT, STOP, OR REVERSE THE (1) LOSS OF INSULIN-PRODUCING BETA CELLS AND (2) THE IMMUNE SYSTEM'S ATTACK ON BETA CELLS. BREAKTHROUGH T1D IS ACCELERATING OUR WORK IN CURING T1D BY FOCUSING ON THREE AREAS THAT HAVE ADVANCED DRAMATICALLY OVER THE YEARS: EARLY DETECTION OF T1D, CELL THERAPIES, AND DISEASE-MODIFYING THERAPIES. EARLY DETECTION OF T1D: FOCUS ON EXPANDING AWARENESS OF AND ACCESS TO SCREENING FOR T1D-RELATED AUTOANTIBODIES, AND MONITORING FOR PEOPLE WHO TEST POSITIVE. DONOR-FUNDED RESEARCH HAS DISCOVERED THAT HAVING TWO OR MORE T1D-SPECIFIC ANTIBODIES MEANS THAT YOU HAVE AN ALMOST 100% CHANCE OF DEVELOPING DIABETES IN YOUR LIFETIME. WITH ONE BLOOD TEST, YOU CAN FIND OUT--BEFORE SYMPTOMS APPEAR--IF YOU ARE AT RISK. THIS CAN REDUCE THE RISK OF DIABETIC KETOACIDOSIS AND HOSPITALIZATION AT THE ONSET OF SYMPTOMS AND IDENTIFY PEOPLE WHO CAN TAKE PART IN CLINICAL TRIALS TO DELAY OR PREVENT T1D. CELL THERAPIES: FOCUS ON REPLACING INSULIN-PRODUCING BETA CELLS FROM OUTSIDE SOURCES SUCH AS STEM CELLS OR NON-HUMAN CELLS. THROUGH DONOR-FUNDED RESEARCH, WE NOW KNOW THAT WHEN SOMEONE HAS T1D, THEIR OWN BODY BEGINS ATTACKING AND DESTROYING THE BETA CELLS THAT CREATE INSULIN. IF WE CAN REPLACE BETA CELLS, WE CAN HELP CURE T1D. THERE IS EARLY BUT CRUCIAL PROGRESS SEEN IN RECENTLY REPORTED CLINICAL TRIALS WHERE BETA CELL REPLACEMENT HAS MADE ADVANCES TOWARD INSULIN THERAPY INDEPENDENCE, BETTER T1D MANAGEMENT, AND LONGEVITY OF THE THERAPIES. DISEASE-MODIFYING THERAPIES: RESEARCH HAS SHOWN THAT A PERSON'S IMMUNE SYSTEM MISTAKENLY DESTROYS THE BODY'S BETA CELLS, RENDERING THE PERSON INSULIN-THERAPY DEPENDENT FOR LIFE. IF WE CAN KEEP THE IMMUNE SYSTEM FROM ATTACKING AND DESTROYING BETA CELLS; PROTECT EXISTING, HEALTHY BETA CELLS; SPUR BETA CELL GROWTH; AND DEVELOP TREATMENTS THAT CAN SLOW, HALT, OR REVERSE T1D, AT ANY AGE OR STAGE OF THE DISEASE, WE WILL BE ON THE PATHWAY TO PREVENTION AND CURES FOR T1D. IMPROVING LIVES T1D BRINGS WITH IT DAILY STRUGGLES AND STRESSES THAT MAKE THE CHALLENGES OF LIVING A HEALTHY AND LONG LIFE WITH T1D VERY REAL. BREAKTHROUGH T1D FIGHTS EVERY DAY TO ADVANCE RESEARCH THAT REDUCES THE BURDEN OF LIVING WITH T1D AND KEEPS PEOPLE AS HEALTHY AS POSSIBLE UNTIL WE HAVE CURES. SPECIFICALLY, WE ARE STRIVING TO IMPROVE LIVES BY ACCELERATING THE DEVELOPMENT OF DRUGS, DEVICES, BEHAVIORAL HEALTH INTERVENTIONS, AND COMBINATIONS OF THESE TO IMPROVE SHORT- AND LONG-TERM HEALTH OUTCOMES AND QUALITY OF LIFE, THROUGH THE FOLLOWING THREE PROGRAMS: GLUCOSE CONTROL: WE KNOW THAT FEWER THAN 30% OF PEOPLE WITH T1D IN THE U.S. CONSISTENTLY MAINTAIN TARGET BLOOD-GLUCOSE LEVELS--MEANING THAT 70% ARE AT RISK OF SERIOUS HEALTH ISSUES. AIMING TO ENSURE OUR COMMUNITY IS HEALTHY WHEN CURES ARE FOUND, WE WILL CONTINUE TO FOCUS ON HELPING THOSE WITH T1D MANAGE GLUCOSE LEVELS AND OVERALL METABOLIC BALANCE, INCLUDING IMPROVED ARTIFICIAL PANCREAS TECHNOLOGY, DEVELOPING NEXT-GENERATION INSULINS, AND DEVELOPING NEW DRUGS THAT CONTROL GLUCOSE AND OTHER METABOLIC FACTORS IN NOVEL WAYS. COMPLICATIONS: FOCUS ON ACCELERATING THERAPIES THAT PREVENT AND TREAT EYE, KIDNEY, AND HEART DISEASE. MORE THAN 90% OF PEOPLE WITH T1D DEVELOP SOME LEVEL OF EYE DISEASE WITHIN 20 YEARS OF DIAGNOSIS, 1 IN 4 DEVELOP KIDNEY DISEASE, AND HEART ATTACKS AND STROKES CAUSE APPROXIMATELY 3 OUT OF EVERY 4 DEATHS IN PEOPLE WITH T1D. BREAKTHROUGH T1D DIRECTS FUNDS TO DEVELOP AND IMPROVE EYE, KIDNEY, AND HEART DISEASE TREATMENTS, SO THAT PEOPLE AT RISK CAN TAKE STEPS TO INTERVENE EARLY IN THE DISEASE PROCESS. PSYCHOSOCIAL HEALTH: FOCUS ON REDUCING THE PSYCHOSOCIAL CHALLENGES OF T1D. RESEARCH HAS SHOWN THAT THE BURDEN OF LIVING WITH T1D TAKES A TOLL BEYOND THE PHYSICAL COMPLICATIONS, OFTEN AFFECTING PEOPLE'S SOCIAL, BEHAVIORAL, AND EMOTIONAL WELL-BEING, KNOWN COLLECTIVELY AS PSYCHOSOCIAL HEALTH. WE AIM TO REDUCE THE CHALLENGES THROUGH INCREASING THE NUMBER OF AND PROVIDING ACCESS TO PSYCHOLOGISTS TRAINED IN T1D, SUPPORTING RESEARCH INITIATIVES TO IMPROVE PSYCHOSOCIAL HEALTH AND OUTCOMES, AND EDUCATING THE T1D COMMUNITY ABOUT THE PSYCHOSOCIAL IMPACT OF THE DISEASE. FORM 990, PART III, LINE 4B: PUBLIC EDUCATION BREAKTHROUGH T1D IS UNIQUELY QUALIFIED TO PROVIDE PUBLIC EDUCATION ABOUT TYPE 1 DIABETES AND ITS COMPLICATIONS. BREAKTHROUGH T1D'S EFFORTS IMPACT NOT ONLY THE MILLIONS OF PEOPLE LIVING WITH T1D, THEIR FAMILIES, AND THE GENERAL PUBLIC, BUT ALSO THOSE AT RISK FOR DEVELOPING THE DISEASE. T1D STRIKES BOTH CHILDREN AND ADULTS, AND THE CRITICAL ADJUSTMENT PERIOD FOLLOWING A DIAGNOSIS CAN BE OVERWHELMING. THAT'S WHY WE SUPPORT FAMILIES AND INDIVIDUALS NAVIGATING THIS CHALLENGING TIME. WE ALSO EDUCATE PEOPLE ABOUT THE WARNING SIGNS OF T1D, AIMED AT ENSURING TIMELY DIAGNOSES AND REDUCING THE POTENTIAL CATASTROPHIC CONSEQUENCES OF UNDIAGNOSED T1D. BREAKTHROUGH T1D ALSO PROVIDES INFORMATION AND UPDATES ABOUT CURRENT RESEARCH DIRECTIONS AND PROGRESS ABOUT HUMAN CLINICAL TRIALS THAT ARE SEEKING PARTICIPANTS (INCLUDING THROUGH OUR CLINICAL TRIALS CONNECTION MATCHING TOOL: WWW.BREAKTHROUGHT1D.ORG/CLINICAL-TRIALS) AS WELL AS OUR HEALTH CARE PROFESSIONAL EDUCATION RESOURCES. THROUGH ALL OF OUR NATIONAL U.S. CHAPTERS; FIVE INTERNATIONAL AFFILIATES IN AUSTRALIA, CANADA, ISRAEL, THE NETHERLANDS, AND UNITED KINGDOM; BREAKTHROUGH T1D DRIVES TOWARD CURES WHILE MEETING THE T1D COMMUNITY'S DIVERSE NEEDS, CONNECTING PEOPLE WITH LOCAL SUPPORT, EXPERT RESOURCES, AND THE GLOBAL EFFORT TO CREATE A WORLD WITHOUT T1D. FORM 990, PART III, LINE 4C: RESEARCH SUPPORT BREAKTHROUGH T1D'S IN-HOUSE TEAM OF SKILLED AND CREDENTIALED SCIENTIFIC, POLICY, AND GOVERNMENT RELATIONS PROFESSIONALS PLAYS A CRITICAL ROLE IN LEADING AND SUPPORTING THE RESEARCH STRATEGY AND DISTRIBUTION OF RESEARCH FUNDS FROM BREAKTHROUGH T1D - AND OUR PARTNER ORGANIZATIONS - TOWARD CREATING A WORLD WITHOUT T1D. OUR PROFESSIONALS IDENTIFY, EVALUATE, AND INFLUENCE GROUNDBREAKING RESEARCH FOR FUNDING AND WORK WITH OTHER FOUNDATIONS, GOVERNMENTS, AND INDUSTRY PARTNERS TO ACCELERATE OUR SHARED MISSION. BREAKTHROUGH T1D PROFESSIONALS WORK WITH REGULATORY AND POLICY OFFICIALS TO ENSURE RESEARCH CAN PROCEED WITHOUT DELAY AND THAT ADVANCES ARE WELL UNDERSTOOD BY HEALTHCARE DECISION MAKERS AND HEALTHCARE PROFESSIONALS. AS PART OF THESE EFFORTS, BREAKTHROUGH T1D ORGANIZES AND FUNDS SCIENTIFIC MEETINGS, SYMPOSIA, AND CONFERENCES TO ENSURE THAT BREAKTHROUGH T1D'S RESEARCH STRATEGY IS ALIGNED WITH THE NEEDS OF THE T1D COMMUNITY AND ALLOW OUR EXPERTS TO PROVIDE SCIENTIFIC AND CLINICAL CARE UPDATES ON THE RESEARCH WE FUND. THIS EFFORT ENSURES THAT ALL THE RESEARCH IS CONTINUALLY SHARED AND BUILT UPON BY T1D RESEARCHERS AND HEALTHCARE PROFESSIONALS AROUND THE GLOBE. THE STRATEGIC ADVISORY PANEL (SAP) IS COMPOSED OF FIVE ESTABLISHED T1D EXPERTS IN VARIOUS ASPECTS OF THE FIELD, INCLUDING PEDIATRIC ENDOCRINOLOGY, PREVENTION, AND TREATMENT OF T1D, IMMUNOTHERAPIES, REGULATORY, AND DRUG DEVELOPMENT. THE SAP CONTRIBUTES TO BREAKTHROUGH T1D SCIENTISTS' STRATEGIC PLANNING REGARDING RESEARCH FUNDING GOALS AND PRIORITIES. BREAKTHROUGH T1D BRINGS TOGETHER THE BEST MINDS IN THE FIELD, WHICH ENHANCES BREAKTHROUGH T1D'S ABILITY TO FORECAST FUTURE SCIENTIFIC DIRECTION, JUDGE THE POTENTIAL EFFECTIVENESS OF NEW PATHWAYS, AND IDENTIFY GAPS WHERE OUR FUNDING CAN MAKE THE MOST IMPACT. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 REVIEW PROCESS BREAKTHROUGH T1D HAS A RIGOROUS STANDARD APPROACH TO REVIEWING ITS 990. THE ORGANIZATION'S ACCOUNTING MANAGER WORKS WITH ITS OUTSIDE TAX PREPARERS TO PREPARE THE RETURN AND ALL SUPPORTING SCHEDULES. THE DRAFT RETURN IS REVIEWED BY A NUMBER OF INDIVIDUALS, INCLUDING BREAKTHROUGH T1D'S CHIEF FINANCIAL OFFICER, OTHER EXECUTIVES, ITS EXTERNAL SENIOR TAX ADVISOR AND OTHERS AS NECESSARY TO ENSURE ACCURACY. ANY QUESTIONS AND CHANGES WITH RESPECT TO THE DRAFT RETURNS ARE ADDRESSED. FOLLOWING THIS PROCESS, THE RETURN IS REVIEWED BY BREAKTHROUGH T1D'S AUDIT AND RISK COMMITTEE OF THE BOARD OF DIRECTORS WITH ITS OUTSIDE TAX ADVISORS. ONCE APPROVED, THE RETURN IS DISTRIBUTED TO ALL MEMBERS OF BREAKTHROUGH T1D'S BOARD OF DIRECTORS FOR REVIEW AND COMMENT BEFORE IT IS FILED WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C CONFLICT OF INTEREST POLICY COVERED PERSONS COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM AND ACKNOWLEDGE THE BREAKTHROUGH T1D CODE OF ETHICS AT THE BEGINNING OF EACH FISCAL YEAR. COVERED PERSONS INCLUDE: MEMBERS OF THE INTERNATIONAL BOARD OF DIRECTORS, DIRECTORS EMERITUS, MEMBERS OF THE GLOBAL MISSION BOARD, CHAPTER DIRECTORS AND OFFICERS, DIRECTORS OF THE T1D FUND, AND MEMBERS OF THE T1D FUND INVESTMENT COMMITTEE. WHEN A CONFLICT IS DISCLOSED, THE COVERED PERSON SHALL ABSTAIN FROM PARTICIPATING IN DECISIONS AND/OR DISCUSSIONS INVOLVING BREAKTHROUGH T1D'S BUSINESS OR RELATIONSHIP WITH THE RELEVANT THIRD PARTY. IF THE COVERED PERSON IS ASKED TO ABSTAIN, THE COVERED PERSON MAY STILL BE PERMITTED TO STATE HIS OR HER POSITION ON SUCH MATTER AND TO ANSWER PERTINENT QUESTIONS AND INQUIRIES RELATING THERETO. THE COVERED PERSON MAY BE ASKED TO LEAVE THE MEETING DURING THE DISCUSSION OF AND/OR VOTE ON THE MATTER INVOLVING THE RELEVANT THIRD PARTY. FORM 990, PART VI, SECTION B, LINE 15 EXECUTIVE COMPENSATION POLICY BREAKTHROUGH T1D'S BOARD OF DIRECTORS CHARGES A TALENT AND COMPENSATION COMMITTEE TO DEVELOP AND RECOMMEND A COMPENSATION PHILOSOPHY THAT APPLIES TO ALL EMPLOYEES OF THE ORGANIZATION, INCLUDING RECOMMENDATIONS REGARDING THE COMPENSATION AND BENEFITS OF ORGANIZATION SENIOR MANAGEMENT FOR APPROVAL BY THE BOARD OF DIRECTORS. THE COMMITTEE WORKS IN COLLABORATION WITH THE CEO AND THE CHIEF HUMAN RESOURCES OFFICER AND OTHER SENIOR STAFF PERSONNEL IN THE BREAKTHROUGH T1D HUMAN RESOURCES DEPARTMENT TO ENSURE THAT 1) THE ORGANIZATION'S TALENT STRATEGY SUPPORTS AND IS ALIGNED WITH ITS OVERALL ORGANIZATION STRATEGIES; 2) BREAKTHROUGH T1D IS IN COMPLIANCE WITH IRS GUIDELINES FOR DETERMINING REASONABLENESS IN PAY PRACTICES; AND 3) OVERALL COMPENSATION FOR THE ORGANIZATION'S KEY EXECUTIVES IS COMPETITIVE AND ALIGNED WITH PAY PHILOSOPHY. TO ATTRACT AND RETAIN TOP SCIENTIFIC AND EXECUTIVE TALENT TO ADVANCE ITS MISSION, THE ORGANIZATION PAYS COMPETITIVE AND APPROPRIATE SALARIES AS DETERMINED BY ANALYSIS OF RELIABLE DATA AND INPUT FROM INDEPENDENT THIRD-PARTY CONSULTANTS. THE REVIEW OF ORGANIZATION EXECUTIVE COMPENSATION AND BENEFITS UNDER THE PROCEDURES NOTED ABOVE IS COMPLETED ANNUALLY BY AN INDEPENDENT COMPENSATION COMMITTEE, AND THE BASIS FOR THEIR DETERMINATION IS DOCUMENTED CONTEMPORANEOUSLY IN THE MINUTES OF THE COMMITTEE'S MEETINGS, INCLUDING MOST RECENTLY ON JUNE 30, 2024. SIMILARLY, A SEPARATE TALENT AND COMPENSATION COMMITTEE OF THE T1D FUND IS CHARGED WITH ENSURING THAT 1) THE FUND'S TALENT STRATEGY SUPPORTS AND IS ALIGNED WITH ITS OVERALL ORGANIZATION STRATEGIES; 2) BREAKTHROUGH T1D IS IN COMPLIANCE WITH IRS GUIDELINES FOR DETERMINING REASONABLENESS IN PAY PRACTICES; AND 3) OVERALL COMPENSATION FOR THE FUND'S KEY EXECUTIVES IS COMPETITIVE AND ALIGNED WITH PAY PHILOSOPHY. FORM 990, PART VI, SECTION C, LINE 19 PUBLIC DOCUMENTS THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE: WWW.BREAKTHROUGHT1D.ORG. THE PUBLIC MAY ACCESS COPIES OF BREAKTHROUGH T1D'S W-9, ANNUAL REPORTS, 990 TAX RETURNS, 501(C)(3) IRS LETTER, AND AUDITED FINANCIALS, AT THE FOLLOWING LINK: HTTPS://WWW.BREAKTHROUGHT1D.ORG/ABOUT/FINANCIALS/ T1D FUND A BREAKTHROUGH T1D VENTURE LLC C/O BREAKTHROUGH T1D - 200 VESEY ST NEW YORK NY 10281 274967989 FUNDR/INVEST DE 3664908 199938927 BREAKTHROUGH T1D SCHEDULE R, PART I, LINE (1B) THE PRIMARY ACTIVITY FOR THE T1D FUND IS FUNDRAISING AND INVESTING IN TYPE 1 DIABETES RESEARCH. PLEASE SEE DETAILED DESCRIPTION ON SCHEDULE O, PART III, LINE 4A, STATEMENT OF PROGRAM SERVICE ACCOMPLISHMENTS FOR RESEARCH GRANTS.